当前位置： SCI文献检索 > CLINICAL DRUG INVESTIGATION期刊下所有文献 > Efficacy of Off-Label Topical Treatments for the Management of Androgenetic Alopecia: A Review.

Efficacy of Off-Label Topical Treatments for the Management of Androgenetic Alopecia: A Review.

Abstract：

:Androgenetic alopecia (AGA) is characterized by non-scarring follicle miniaturization. Despite the success of approved therapies, commonly reported side effects and the need for continual use has led to the investigation of alternative therapies. The aim of this paper is to critically review the success of off-label, topical monotherapies for treatment of AGA in men. A literature search was conducted to obtain randomized, controlled and blinded studies that investigated off-label, topical, monotherapies in male patients. Hair density, hair diameter and hair growth were used to evaluate treatment success. Fourteen off-label topical therapies were investigated among the 16 studies that met inclusion criteria. Nine off-label therapies were reported to produce a significantly greater improvement in hair restoration parameters (e.g. mean change from hair count and hair diameter) as compared to placebo (p < 0.05 for all treatments). In two studies, procyanidin oligomers exhibited greater efficacy over vehicle with response to mean change in hair density (hairs/cm2) (ps < 0.0001 at Week 24). In conclusion, prostaglandin analogs and polyphenols, such as latanoprost and procyanidin oligomers, can improve hair restoration parameters in male AGA patients, possibly through targeting mechanisms proposed in the etiology of AGA. The current evidence suggests short-term (24 weeks) use may provide benefit for hair loss patients; however, long-term efficacy and safety data are required.

journal_name

Clin Drug Investig

journal_title

Clinical drug investigation

authors

Gupta AK,Mays RR,Versteeg SG,Shear NH,Piguet V,Piraccini BM

doi

10.1007/s40261-018-00743-8

subject

Has Abstract

pub_date

2019-03-01 00:00:00

pages

233-239

issue

3

eissn

1173-2563

issn

1179-1918

pii

10.1007/s40261-018-00743-8

journal_volume

39

pub_type

杂志文章,评审

相关文献

CLINICAL DRUG INVESTIGATION文献大全
  • Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice.

    abstract：OBJECTIVE:To compare the real-life treatment of acute exacerbations of chronic bronchitis (AECBs) using moxifloxacin tablets or one of the oral macrolides azithromycin, clarithromycin or roxithromycin in terms of symptom relief, time until improvement and cure, overall efficacy and tolerability. METHODS:This prospecti...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,多中心研究

    doi：10.2165/00044011-200626120-00007

    authors： Schaberg T,Möller M,File T,Stauch K,Landen H

    更新日期：2006-01-01 00:00:00

  • Efficacy of L-carnitine in reducing hyperammonaemia and improving neuropsychological test performance in patients with hepatic cirrhosis : results of a randomised trial.

    abstract：OBJECTIVES:To determine the efficacy of L-carnitine in reducing hyperammonaemia and improving neuropsychological performance in patients with hepatic cirrhosis and subclinical hepatic encephalopathy (SHE). DESIGN:Randomised, parallel group, controlled trial. PATIENTS AND METHODS:The study enrolled 31 patients with he...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.2165/00044011-200222001-00002

    authors： Cecere A,Ciaramella F,Tancredi L,Romano C,Gattoni A

    更新日期：2002-11-01 00:00:00

  • Topical application of dexamethasone to prevent cerebral vasospasm after aneurysmal subarachnoid haemorrhage: a pilot study.

    abstract：BACKGROUND AND OBJECTIVE:Cerebral vasospasm is a common and serious complication of aneurysmal subarachnoid haemorrhage (SAH). Many studies have revealed a role of inflammation in the development of cerebral vasospasm. This study aimed to investigate whether topically administered dexamethasone could attenuate vasospas...

    journal_title：Clinical drug investigation

    pub_type： 临床试验,杂志文章

    doi：10.2165/00044011-200727120-00004

    authors： Fei L,Golwa F

    更新日期：2007-01-01 00:00:00

  • Drug interactions with levothyroxine therapy in patients with hypothyroidism: observational study in general practice.

    abstract：BACKGROUND AND OBJECTIVES:Several drugs may interact with levothyroxine and reduce its bioavailability. The aim of this study was to analyse the Italian general practice patients with hypothyroidism from 2002-2011, in terms of variation of thyroid-stimulating hormone (TSH) levels, number of levothyroxine prescriptions ...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-015-0271-0

    authors： Trifirò G,Parrino F,Sultana J,Giorgianni F,Ferrajolo C,Bianchini E,Medea G,Benvenga S,Cricelli I,Cricelli C,Lapi F

    更新日期：2015-03-01 00:00:00

  • Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study.

    abstract：BACKGROUND AND OBJECTIVE:Tendon rupture can result from fluoroquinolone exposure. The objective of this study was to quantify relative and absolute risk and determine how risk is affected by timing of exposure. METHODS:The UK Health Improvement Network primary care database was used to perform a nested case-control st...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-018-0729-y

    authors： Morales DR,Slattery J,Pacurariu A,Pinheiro L,McGettigan P,Kurz X

    更新日期：2019-02-01 00:00:00

  • Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm.

    abstract：BACKGROUND AND OBJECTIVE:The skeletal muscle relaxant tizanidine is approved by the US FDA and the European Medicines Agency for treating spasticity and is supplied as tablets for oral administration. However, tizanidine has a poor bioavailability, due to extensive first-pass metabolism. Therefore, the nasal route of a...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s40261-013-0137-2

    authors： Vitale DC,Piazza C,Sinagra T,Urso V,Cardì F,Drago F,Salomone S

    更新日期：2013-12-01 00:00:00

  • 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.

    abstract：:Intramuscular 17 α-hydroxyprogesterone caproate (Makena(®)), a synthetic progestin, is indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of a singleton spontaneous preterm birth. Makena(®) reduces the risk of preterm birth in this patient population, and is associated...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-013-0060-6

    authors： Hines M,Lyseng-Williamson KA,Deeks ED

    更新日期：2013-03-01 00:00:00

  • Salmeterol/Fluticasone Propionate in a Single Inhaler is Superior to Budesonide Alone in Control of Chinese Asthmatic Adults : An Open-Label, Randomised, 6-Week Study.

    abstract：OBJECTIVE AND DESIGN:There is comparatively little information on asthma management in China. A multicentre, randomised, open-label, parallel-group, 6-week treatment study was conducted to evaluate the efficacy and safety of salmeterol/fluticasone propionate combination treatment in Chinese adult asthmatic patients. S...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.2165/00044011-200424100-00004

    authors： Zhong NS,Ping ZJ,Humphries MJ,Xin D

    更新日期：2004-01-01 00:00:00

  • Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an open-label, observational, multicentre, general practice-based study.

    abstract：BACKGROUND AND OBJECTIVES:Hypertension, one of the major treatable cardiovascular (CV) risk factors, usually occurs in association with other major risk factors. As well as providing rapid blood pressure (BP) goal attainment, antihypertensive therapy should also provide reductions in CV events and mortality in a wide r...

    journal_title：Clinical drug investigation

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.2165/00044011-200828110-00001

    authors： Ogilvie RI,Anand S,Roy P,De Souza S,PEACH investigators.

    更新日期：2008-01-01 00:00:00

  • Oral Teicoplanin as an Alternative First-Line Regimen in Clostridium difficile Infection in Elderly Patients: A Case Series.

    abstract：BACKGROUND:Elderly patients are more susceptible to Clostridium difficile infections (CDIs). Despite existing guidelines, there is no specific treatment for CDI in geriatrics. Vancomycin is commonly used in the treatment of CDI. Teicoplanin is an alternative glycopeptide which recently received marketing authorization ...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-017-0524-1

    authors： Davido B,Leplay C,Bouchand F,Dinh A,Villart M,Le Quintrec JL,Teillet L,Salomon J,Michelon H

    更新日期：2017-07-01 00:00:00

  • Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy.

    abstract：:Sublingual buprenorphine [Subutex(R)] is used to treat opioid dependence. However, illicit intravenous (IV) injection of buprenorphine is a widespread problem. This survey investigated the IV misuse of buprenorphine among patients receiving drug replacement therapy at the Drug Addiction Centre in Udine, Italy. All pat...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.2165/11536020-000000000-00000

    authors： Moratti E,Kashanpour H,Lombardelli T,Maisto M

    更新日期：2010-01-01 00:00:00

  • Investigation on Dabigatran Etexilate and Worsening of Renal Function in Patients with Atrial fibrillation: The IDEA Study.

    abstract：BACKGROUND AND OBJECTIVES:Warfarin-related nephropathy is an unexplained acute kidney injury, and may occur in patients with supratherapeutic INR, in the absence of overt bleeding. Similar findings have been observed in rats treated with dabigatran etexilate. We conducted a prospective study in dabigatran etexilate-tre...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-018-0742-1

    authors： Molteni M,Crippa M,Orenti A,Polo Friz H,Menghini A,Tramacere P,Marano G,Cimminiello C,Boracchi P

    更新日期：2019-04-01 00:00:00

  • Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study.

    abstract：BACKGROUND AND OBJECTIVE:Hypertension remains a major global health problem, and evidence suggests that the majority of patients will require two or more antihypertensive agents in order to reach specified BP targets. Combining two drugs from different classes has the potential to target different aspects of hypertensi...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.2165/00044011-200929070-00001

    authors： Barrios V,Brommer P,Haag U,Calderón A,Escobar C

    更新日期：2009-01-01 00:00:00

  • Linguistic adaptation and validation of the Spanish version of the Benign Prostatic Hyperplasia-Patient Impact Measure (BPH-PIM).

    abstract：BACKGROUND:The Benign Prostatic Hyperplasia-Patient Impact Measure (BPH-PIM) is a self-reported quality-of-life questionnaire for measuring the impact of urinary/prostate symptoms on the quality of life of patients with BPH. The aim of the present study was to adapt the original instrument to Spanish (for use in Spain)...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.2165/00044011-200626020-00005

    authors： Llorente C,Ruiz M,Rejas Gutiérrez J,Esteban M,Villasante F,Hareendran A

    更新日期：2006-01-01 00:00:00

  • Basal and Bolus Insulin Dose Changes after Switching Basal Insulin to Insulin Degludec in Patients with Type 1 Diabetes Mellitus: A Pilot Study.

    abstract：BACKGROUND AND OBJECTIVES:Ultra-long-acting insulin degludec (DEG) has a longer duration of action and less daily variability relative to other basal insulin (BI), and thus may benefit patients with type 1 diabetes mellitus (T1DM). We examined the impact of switching BI to DEG on glycemic control and insulin dose in T1...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-017-0541-0

    authors： Hamamoto Y,Honjo S,Fujimoto K,Tokumoto S,Ikeda H,Wada Y,Koshiyama H

    更新日期：2017-09-01 00:00:00

  • Facial Paralysis Following Influenza Vaccination: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System Database.

    abstract：BACKGROUND AND OBJECTIVE:Several cases of facial paralysis have been reported following influenza vaccination; however, recent surveillance studies have not shown an increased risk. In this study, we analyzed the vaccine adverse event reporting system (VAERS) data to determine whether the facial paralysis reporting rat...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-020-00952-0

    authors： Kamath A,Maity N,Nayak MA

    更新日期：2020-09-01 00:00:00

  • Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index.

    abstract：OBJECTIVE:Weight gain during insulin therapy can be a challenging problem in already overweight type 2 diabetes mellitus patients, affecting treatment compliance and long-term prognosis. The analogue insulin detemir has been reported to have a weight-sparing effect compared with other basal insulins. This pooled analys...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.2165/00044011-200727040-00007

    authors： Raslová K,Tamer SC,Clauson P,Karl D

    更新日期：2007-01-01 00:00:00

  • Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis: a prospective, randomized trial.

    abstract：BACKGROUND AND OBJECTIVE:As a β-adrenoceptor antagonist (β-blocker), esmolol can reduce cardiac output and the phosphodiesterase III inhibitor milrinone has been shown to improve heart contractility in patients with septic shock. This study was performed to assess the effects of esmolol combined with milrinone in patie...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s40261-015-0325-3

    authors： Wang Z,Wu Q,Nie X,Guo J,Yang C

    更新日期：2015-11-01 00:00:00

  • Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions.

    abstract：BACKGROUND AND OBJECTIVE:Several systematic reviews and meta-analyses have been conducted including an analysis to investigate the difference between ethnic groups in the glucose-lowering efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors. This study assessed the factors related to the glucose-lowering efficacy and ...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s40261-016-0478-8

    authors： Fujita K,Kaneko M,Narukawa M

    更新日期：2017-03-01 00:00:00

  • Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in China.

    abstract：:Mecapegfilgrastim (HHPG-19K) is a long-acting pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) that is administered subcutaneously as prophylaxis once per chemotherapy cycle as a weight-adjusted dose of 100 µg/kg or as a 6 mg fixed dose. It is approved in China to reduce the incidence of inf...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,评审

    doi：10.1007/s40261-019-00836-y

    authors： Al-Salama ZT,Keam SJ

    更新日期：2019-10-01 00:00:00

  • Pharmacokinetic Bioequivalence of Two Inhaled Tiotropium Bromide Formulations in Healthy Volunteers.

    abstract：BACKGROUND AND OBJECTIVE:A novel tiotropium bromide monodose capsule dry powder inhaler (DPI) formulation and device have been developed. The formulation was based on a spray-dried matrix that enhances the aerosolizaton properties, allowing a less active tiotropium metered dose (13 µg/capsule) while maintaining the sam...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s40261-016-0441-8

    authors： Algorta J,Andrade L,Medina M,Kirkov V,Arsova S,Li F,Chi J

    更新日期：2016-09-01 00:00:00

  • Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.

    abstract：BACKGROUND AND OBJECTIVES:Dyslipidaemia is a major cardiovascular risk factor associated with type 2 diabetes mellitus. Saroglitazar (ZYH1) is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity. It has been developed for the treatment of dyslipidaemia an...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s40261-013-0128-3

    authors： Jani RH,Kansagra K,Jain MR,Patel H

    更新日期：2013-11-01 00:00:00

  • Prescription Drug Price Paradox: Cost Analysis of Canadian Online Pharmacies versus US Medicare Beneficiaries for the Top 100 Drugs.

    abstract：BACKGROUND AND OBJECTIVES:Despite the introduction of Medicare Part D (MPD) and 2012 Affordable Care Act (ACA), patients have a cost burden due to increases in drug prices. To overcome cost barriers, some patients purchase their medications from Canadian online pharmacies as Canadian prescription drug prices are believ...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-017-0556-6

    authors： Kim SH,Ryu YJ,Cho NE,Kim AE,Chang J

    更新日期：2017-10-01 00:00:00

  • Pharmacokinetic and pharmacodynamic profiles of a fixed-dose combination of olmesartan medoxomil and amlodipine in healthy Chinese males and females.

    abstract：OBJECTIVES:This study investigated the pharmacokinetics and pharmacodynamics of a fixed-dose combination (FDC) tablet of olmesartan medoxomil 20 mg and amlodipine 5 mg (CS-8663) in healthy Chinese subjects. METHODS:This single-centre, open-label study was conducted in five healthy males and five females aged 18-45 yea...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-012-0026-0

    authors： Chen X,Hu P,Jiang J,Liu T,Zhong W,Liu H,Zhao Q

    更新日期：2012-12-01 00:00:00

  • Diclofenac epolamine (Flector) patch: evidence for topical activity.

    abstract：:This review focuses on previously unpublished clinical and pharmacokinetic data with the diclofenac epolamine (diclofenac hydroxyethylpyrrolidine) patch supporting the hypothesis of a topical effect of this formulation. Previous studies have shown that 1 or 2 weeks of treatment with diclofenac epolamine provides pain ...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,评审

    doi：10.2165/0044011-200929010-00001

    authors： Petersen B,Rovati S

    更新日期：2009-01-01 00:00:00

  • Hospitalization for severe bacterial infections in children after exposure to NSAIDs: a prospective adverse drug reaction reporting study.

    abstract：BACKGROUND:NSAIDs are widely used to treat fever and pain in children, but their possible role in the progression of some bacterial infections is controversial. OBJECTIVE:This study was performed to analyse reported cases of severe bacterial infection associated with NSAID exposure in children admitted for this reason...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.2165/11532890-000000000-00000

    authors： Leroy S,Marc E,Bavoux F,Tréluyer JM,Gendrel D,Bréart G,Pons G,Chalumeau M

    更新日期：2010-01-01 00:00:00

  • Changes in Cardiac Function After a Single Intravenous Administration of CKD-712 in Healthy Male Volunteers.

    abstract：BACKGROUND AND OBJECTIVES:CKD-712, a candidate treatment for septic shock, acts by increasing cardiac output. This study investigated changes in the pharmacodynamics, pharmacokinetics, and tolerability of CKD-712 after a single intravenous administration. METHODS:A dose-block-randomized, double-blind, placebo-controll...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s40261-017-0494-3

    authors： Park SI,Kim J,Yu KS,Jang IJ,Lee S

    更新日期：2017-04-01 00:00:00

  • Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.

    abstract：BACKGROUND AND OBJECTIVES:The new oral anticoagulants (NOACs) are used for the prevention of thromboembolic complications in patients with non-valvular atrial fibrillation (AF) and those at risk of deep venous thrombosis. Their rapid onset of action and predictable pharmacokinetic and pharmacodynamic profiles make them...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-016-0436-5

    authors： Acanfora D,Acanfora C,Scicchitano P,Longobardi M,Furgi G,Casucci G,Lanzillo B,Dentamaro I,Zito A,Incalzi RA,Ciccone MM

    更新日期：2016-10-01 00:00:00

  • Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults.

    abstract：BACKGROUND AND OBJECTIVES:Dasotraline is a novel inhibitor of dopamine and norepinephrine reuptake currently being investigated in clinical studies for the treatment of attention-deficit/hyperactivity disorder (ADHD). Uniquely, relative to current ADHD medications, dasotraline has a slow absorption and long elimination...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-015-0358-7

    authors： Hopkins SC,Sunkaraneni S,Skende E,Hing J,Passarell JA,Loebel A,Koblan KS

    更新日期：2016-02-01 00:00:00

  • Risk Factors for and Incidence of Seizures in Metastatic Castration-Resistant Prostate Cancer: A Real-World Retrospective Cohort Study.

    abstract：BACKGROUND AND OBJECTIVE:This real-world study assessed the prevalence, risk factors for, and incidence of seizures in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS:Patients with mCRPC were selected from MarketScan Commercial and Medicare Supplemental Databases between 1 January 2009 a...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-017-0578-0

    authors： Dharmani C,Bonafede M,Krivoshik A

    更新日期：2017-12-01 00:00:00